| Literature DB >> 16224068 |
Yasunori Takata1, Van Chu, Alan R Collins, Christopher J Lyon, Wei Wang, Florian Blaschke, Dennis Bruemmer, Evren Caglayan, William Daley, Jitsuo Higaki, Michael C Fishbein, Rajendra K Tangirala, Ronald E Law, Willa A Hsueh.
Abstract
Angiotensin II (Ang II) is a powerful accelerator of atherosclerosis. Herein, we describe a novel transcription mechanism through which Ang II inhibits macrophage expression of the ATP-binding cassette transporter A1 (ABCA1), a key regulator of reverse cholesterol transport. We demonstrate that chronic Ang II infusion substantially promotes macrophage infiltration, foam cell formation, and atherosclerosis in low-density lipoprotein receptor-deficient mice and significantly reduces ABCA1 expression in peripheral macrophages. Administration of the Ang II type 1 receptor blocker valsartan inhibited Ang II-induced ABCA1 mRNA repression, macrophage cholesterol accumulation, and atherosclerosis. Ang II treatment reduced ABCA1 promoter activity of in vitro cultured mouse peritoneal macrophages, inducing fos-related antigen 2 (Fra2) protein binding to an ABCA1 promoter E-box motif, a site known to negatively regulate macrophage ABCA1 transcription. Valsartan pretreatment blocked Fra2 binding to the ABCA1 promoter, and Fra2 small interfering RNA pretreatment attenuated Ang II-mediated ABCA1 transcriptional inhibition, confirming the role of Fra2 in this process. This new evidence suggests that Ang II, a well-known proinflammatory and pro-oxidative factor, alters macrophage cholesterol homeostasis by repressing ABCA1 to promote foam cell formation and atherosclerosis.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16224068 DOI: 10.1161/01.RES.0000190400.46267.7e
Source DB: PubMed Journal: Circ Res ISSN: 0009-7330 Impact factor: 17.367